newsfilter
← Latest News
GlobeNewswire·

Ikena Oncology Receives FDA Fast Track Designation for Novel AHR Antagonist IK-175 in Combination with Nivolumab to Treat Urothelial Carcinoma

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) -- Ikena Oncology, Inc. (NASDAQ:IKNA, "Ikena")), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced that the U.S. Food and